Figure 6
Adoptively transferred CMV-specific CD8+TCM/Eexhibit a better response to antigen challenge in vivo than TEM/E. (A) Schematic of in vivo antigenic stimulation of engrafted CMV-specific TCM/E and TEM/E. (B) Engraftment of CMV-specific TCM/E (squares) or TEM/E (circles) was carried out with (black) or without (white) administration of irradiated CMV pp65-expressing LCLs at days 3, 10, and17; and mean percentage (± SE) of human T cells (CD45+ CD8+) in mouse PBL was determined by flow cytometry (n = 6). *P < .05, engraftment of TCM/E alone versus pp65-driven TCM/E engraftment (unpaired Student t test). (C) On euthanasia at day 28, PBLs were harvested and analyzed by flow cytometry for percentage of Ki-67+ cells in the human T-cell population (left) and for the ability of CD45+ human T cells to cleave the caspase substrate D2R (right).

Adoptively transferred CMV-specific CD8+TCM/Eexhibit a better response to antigen challenge in vivo than TEM/E. (A) Schematic of in vivo antigenic stimulation of engrafted CMV-specific TCM/E and TEM/E. (B) Engraftment of CMV-specific TCM/E (squares) or TEM/E (circles) was carried out with (black) or without (white) administration of irradiated CMV pp65-expressing LCLs at days 3, 10, and17; and mean percentage (± SE) of human T cells (CD45+ CD8+) in mouse PBL was determined by flow cytometry (n = 6). *P < .05, engraftment of TCM/E alone versus pp65-driven TCM/E engraftment (unpaired Student t test). (C) On euthanasia at day 28, PBLs were harvested and analyzed by flow cytometry for percentage of Ki-67+ cells in the human T-cell population (left) and for the ability of CD45+ human T cells to cleave the caspase substrate D2R (right).

Close Modal

or Create an Account

Close Modal
Close Modal